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http://dx.doi.org/10.1016/j.stemcr.2016.05.004SUMMARYThere is an urgent need for an efficient approach to obtain a large-scale and renewable source of functional human vascular smoothmus-
cle cells (VSMCs) to establish robust, patient-specific tissuemodel systems for studying the pathogenesis of vascular disease, and for devel-
opingnovel therapeutic interventions.Here, wehave derived a large quantity of highly enriched functional VSMCs fromhuman induced
pluripotent stem cells (hiPSC-VSMCs). Furthermore, we have engineered 3D tissue rings from hiPSC-VSMCs using a facile one-step
cellular self-assembly approach. The tissue rings are mechanically robust and can be used for vascular tissue engineering and disease
modeling of supravalvular aortic stenosis syndrome. Our method may serve as a model system, extendable to study other vascular pro-
liferative diseases for drug screening. Thus, this report describes an exciting platform technology with broad utility for manufacturing
cell-based tissues and materials for various biomedical applications.INTRODUCTION
Dysfunction of vascular smooth muscle cells (VSMCs)
frequently leads to vascular disease and represents one of
the largest causes of mortality (Michel et al., 2012). Animal
models and primary VSMC culture-based approaches have
been informative in unraveling disease mechanisms
(Chang et al., 2014; Zaragoza et al., 2011). However, there
are significant barriers to progress in the field of basic and
translational research of vascular disease due to (1) signifi-
cant differences in vascular physiology between mice and
humans; (2) limited access to patient VSMCs; and (3) lack
of patient-specific, 3D tissue models that provide a closer
approximation of the in vivo environment. It is also worth
noting that the lack of robust human cell-based disease
models has contributed to the failure of a number of clin-
ical trials that were largely based upon animal studies (Ru-
bin, 2008). Thus, it is necessary to obtain an abundant and
renewable source of functional human VSMCs and to
establish robust, human tissue model systems for studying
the pathogenesis of vascular disease, and for developing
novel therapeutic interventions.
Induced pluripotent stem cell (iPSC) technology holds
great promise for future autologous cellular therapies for
vascular diseases (Tavernier et al., 2013). However, a major
concern is the availability of approaches to differentiateThis is an open access article under the CiPSCs into large quantities of functional VSMCs for
research and therapeutic applications (Dash et al., 2015).
VSMCs have been previously derived from human iPSCs
(hiPSCs) with different approaches (Bajpai et al., 2012;
Cheung et al., 2012; Lee et al., 2009; Patsch et al., 2015;
Wanjare et al., 2013). However, an efficient, large-scale pro-
duction of highly enriched, functional hiPSC-VSMCs
suitable for vascular tissue engineering still awaits to be
established. In this study, hiPSCs from fibroblast cells
were generated using Sendai virus (SeV) vectors. We also
derived a large quantity of highly enriched, functional
hiPSC-VSMCs based on a robust embryoid body (EB)
approach. In addition, we used a scaffold-free, self-assem-
bly approach to engineer robust 3D model vascular tissue
constructs from both normal and disease-specific human
VSMCs.RESULTS
Integration-free hiPSC Generation and
Characterization
Integration-free hiPSCs were generated with neonatal skin
fibroblast cells derived from a healthy female donor using
SeV particles that encode OCT3/4, KLF4, SOX2, and
c-MYC genes. The selected hiPSC clones exhibited aStem Cell Reports j Vol. 7 j 19–28 j July 12, 2016 j ª 2016 19
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typical compact phenotype indistinguishable from human
embryonic stem cells and were positive for pluripotency
markers, including OCT4, NANOG, SSEA-4, and Tra-1-60
(Figure S1A). G-band staining for karyotype analysis indi-
cated that hiPSC clones were karyotypically normal (Fig-
ure S1B) and were also found to be free of SeV vectors
(typically after 15 passages), as shown by RT-PCR (Fig-
ure S1C). The hiPSCs formed teratomas and revealed the
presence of representative tissues that originated from
the three embryonic germ layers (Figure S1D), including
the gastrointestinal epithelium (endoderm), pigmented
epithelium (ectoderm), and hyaline cartilage (mesoderm).
Integration-free hiPSC clones (named as Y6) were then
continuously propagated and used for differentiation and
characterization of VSMCs.
Derivation of Large Quantities of Pure, Functional
VSMCs from hiPSCs
An EB differentiation protocol was used to induce hiPSC
differentiation toward a VSMC lineage. The entire differen-
tiation procedure (shown schematically in Figure 1A) re-
quires 21 days starting from hiPSC culture. Since the
derivation of VSMCs fromhiPSCs using the earlier reported
EB method (Xie et al., 2007) was inefficient and could
not generate large numbers of VSMCs for therapeutic
studies, significantmodifications weremade to the existing
approach, where 80% confluent hiPSCs grown under
feeder-free culture were used to make EBs. Moreover, pure
mTeSR1 (iPSC self-renewal media) and 25% mTeSR1-con-
taining EB differentiation media was used to culture
day 1 and day 2 EBs, respectively. These two modifications
resulted in the production of much healthier EBs and
an abundance of highly enriched VSMCs. After 7 days
of culture in SmGM-2 (a commercially available medium
optimized for VSMC growth), 96.25% ± 2.70%, 90.59% ±
2.20%, and 95.81% ± 0.99% of VSMCs expressed calponin,Figure 1. Characterization of hiPSC-VSMCs
(A) Schematic diagram along with representative images showing the
(B) Immunofluorescence images of cells stained with smooth muscle
VSMCs cultured in SmGM-2 medium for 7 days. Red (SMA and SM-MHC),
represents 50 mm. The Y6 hiPSC line was used to derive VSMCs.
(C) Graph showing percentage of VSMCs positive for calponin, SMA,
(mean ± SD; n = 3 independent experiments).
(D) Fluorescence-activated cell sorting (FACS) data showing VSMC puri
calponin. Goat and mouse IgGs were used as negative controls for SM
(E) Graph showing percentage of VSMCs positive for SM-22a and ca
independent experiments).
(F) Immunofluorescence images of hiPSC-VSMCs cultured in a medium
SM-MHC and elastin. Red (SM-MHC), green (elastin), and blue (nucle
(G) Graph showing percentage of VSMCs positive for SM-MHC and ela
(H) Graph showing percent decrease in cell area in response to agon
determine the statistical difference between different groups (mean
Figures S1–S3 and Tables S1 and S2 for additional controls and suppoa-smooth muscle actin (SMA), and SM-22a, respectively
(Figures 1B, 1C, and S2A). In addition, fluorescence-
activated cell sorting (FACS) analysis showed 91.66% ±
2.78% of hiPSC-VSMCs positive for SM-22a and
91.86% ± 2.05% of hiPSC-VSMCs positive for calponin
(Figures 1D, 1E, and S2B). The expression of mature
VSMCmarkers such as smoothmusclemyosin heavy chain
(SM-MHC) and elastin in hiPSC-VSMCs increased from
3.86% ± 1.80% and 17.32% ± 2.30%, when cultured in
the SmGM-2 growth medium (Figures 1B and 1C), to
87.45% ± 7.10% and 74.65% ± 4.60%, respectively, when
switched to a maturation medium containing 0.5% fetal
bovine serum (FBS) and 1 ng/ml transforming growth
factor b1 (TGF-b1) for 10 days (Figures 1F and 1G). The
expression level of the VSMC mature markers elastin and
SM-MHC in the maturation medium was further validated
by examining the gene-expression level of elastin and by
FACS analysis of SM-MHC-positive cells (Figures S2C and
S2D). A similar pattern of increase in elastin and SM-
MHC was seen after culturing VSMCs in the maturation
medium. The elastin gene-expression level increased
3-fold in the maturation medium compared with that in
the growth-promoting SmGM-2 medium (Figure S2C).
Likewise, an increase in the SM-MHC-positive cells was
seen when the VSMCs were cultured in thematurationme-
dium. The SM-MHC-positive cells increased from 3.24% ±
2.76% in SmGM-2 medium to 79.07% ± 5.89% in the
maturation medium (Figure S2D). In addition, hiPSC-
VSMCs showed contractility in response to agonists such
as carbachol and KCl, measured by quantifying percent
decrease in the cell area. The treatments with carbachol
and KCl induced a 43.31% ± 12.43% and 32.83% ±
10.47% decrease in the cell area, respectively, compared
with PBS control (Figures 1H and S3).
The scalability (Figure 2A) and efficiency of the protocol
were tested in three different hiPSC lines (all from healthyhiPSC-VSMC differentiation method. Scale bar represents 100 mm.
cell markers calponin, SMA, SM-22a, SM-MHC, and elastin in hiPSC-
green (SM-22a, calponin, and elastin), and blue (nuclei). Scale bar
SM-22a, SM-MHC, and elastin in three independent experiments
ty, quantified with smooth muscle cell-specific markers SM-22a and
-22a and calponin, respectively.
lponin in three independent FACS experiments (mean ± SD; n = 3
containing 0.5% FBS and 1 ng/ml TGF-b1 for 10 days and stained for
i). Scale bar represents 50 mm.
stin in three independent experiments.
ists KCl and carbachol. Unpaired Student’s t test was performed to
± SD; n = 3 independent experiments, *p < 0.05, **p < 0.01). See
rting information.
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subjects): Y6 (established in this study; Figure S1), control 1
(Ge et al., 2012), and control 2 (Chen et al., 2013), and
two different batches of FBS (Figures 2B and 2E). The proto-
col consistently generated about 40 3 106 hiPSC-VSMCs
for all three hiPSC lines and both batches of FBS (Figures
2B and 2E). In addition, purities of these hiPSC-VSMCs
were quantified using SM-22a and calponin. Control 1
and control 2 hiPSC-VSMCs were 94.46% ± 1.30% and
97.96% ± 0.40% positive for calponin and 96.85% ±
1.50% and 97.57% ± 1.50% for SM-22a, respectively
(Figures 2C and 2D). Similarly, FBS batch 1- and 2-derived
hiPSC-VSMCs were 96.27% ± 1.90% and 94.36% ±
2.00% positive for calponin and 96.11% ± 1.7% and
96.93% ± 1.4% positive for SM-22a, respectively (Figures
2F and 2G).
VSMCs from different vessels have different embryolog-
ical origin, and these different VSMC subtypes can be
distinguished by their distinct in vitro proliferative re-
sponses to angiotensin II, TGF-b1, and serum (Cheung
et al., 2012). Cell-proliferation assays were performed to
determine the hiPSC-VSMC subtype (Figures S2E–S2G).
MTT assay after 3 days in culture showed an increased
response of hiPSC-VSMCs to serum (Figure S2E), but not
to TGF-b1 and angiotensin II. A similar response of
hiPSC-VSMCs to serum was observed with cell counting
(Figure S2F) and cell-cycle analysis (percentage of prolifer-
ating cells in S and G2-M) (Figure S2G). These results are
consistent with the notion that hiPSC-VSMCsmay contain
a significant population of lateral plate mesoderm-derived
VSMCs that show a proliferative response to serum but
not to TGF-b1 or angiotensin II.
We also found that hiPSC-VSMCs cultured for 7 days in a
ring tissue culture medium with 20% FBS, growth factors
(platelet-derived growth factor-BB [PDGF-BB] and TGF-
b1), and other supplements (CuSO4, proline, glycine,
alanine, and ascorbic acid) proliferated (Figure S4A) and
were able to produce extracellular matrix such as type I
collagen (Figure S4B). This ring culture medium was subse-
quently used to culture 3D hiPSC-VSMC tissue ring con-
structs as described below.Figure 2. Larger-Scale VSMC Derivation from hiPSCs
(A) Schematic diagram showing the procedure for derivation of hiPSC
(B–D) Characterization of hiPSC-VSMCs derived from two other hiPSC
purity was quantified using calponin and SM-22a markers. (B) Res
control 1, and control 2 hiPSCs after 17 days of differentiation (n = 3
positive for calponin or SM-22a in three independent experiments. (D
calponin and SM-22a. Green stains for both calponin and SM-22. Blu
(E–G) Characterization of Y6-VSMCs derived using two different batch
VSMC derivations using two different batches of serum (n = 3 indepen
for calponin and SM-22a in three independent experiments. (G) Imm
Green stains for both calponin and SM-22a. Blue stains for nuclei. Scal
see Figure S2.Robust Tissue Ring Fabrication and Disease Modeling
Previous studies have reported the use of VSMCs derived
from hiPSCs as 2D cell culture models to study vascular dis-
easemechanisms (Ge et al., 2012). However, 3D engineered
tissue models may more closely mimic in vivo vascular
physiology, as cell-cell and cell-matrix interactions are
markedly different between the in vivo environment and
in vitro 2D cell culture. So far, only a few studies have
reported using stem cell-derived VSMCs for tissue engineer-
ing applications using natural or synthetic scaffold mate-
rials (Bajpai et al., 2012; Karamariti et al., 2013; Sundaram
et al., 2014; Wang et al., 2014). However, none have re-
ported using a scaffold-free approach to create 3D engi-
neered vascular tissues. In this study, we employed a
scaffold-free cellular self-assembly approach (Gwyther
et al., 2011b) to generate hiPSC-VSMC tissue rings. Briefly,
hiPSC-VSMCs cultured in SmGM-2 were harvested and
seeded into ring-shaped agarose wells (Figure 3A). hiPSC-
VSMCs aggregated and contracted around the center posts
of the non-adhesive agarose wells and successfully formed
tissue rings within 1 day of seeding.
In preliminary studies, we found that hiPSC-VSMC rings
cultured in SmGM-2 continued to contract in the agarose
wells, resulting in thinning and failure between 4 and
7 days of culture (Figure S4C). Subsequently, hiPSC-VSMCs
were seeded in SmGM-2, then switched to a ring culture
medium with 20% FBS, PDGF-BB, TGF-b1, and other
collagen-promoting supplements 24 hr after cell seeding.
The rings cultured in ring culture medium were stable
and did not show appreciable contraction. hiPSC-VSMC
rings were cultivated in the ring culture medium for 14–
17 days before harvesting for histology and mechanical
testing. Representative photographs of tissue rings derived
fromY6 hiPSC-VSMCs after 14 days in culture are shown in
Figure 3A. Hematoxylin and eosin staining showed highly
cellularized tissue rings (Figure 3B). Masson’s trichrome
staining showed an abundance of collagen in the extracel-
lular matrix of these tissue rings (Figure 3B), which was
also shown by immunostaining for type I collagen (Fig-
ure S4D). Immunohistochemical analyses also showed-VSMCs with high purity.
lines, control 1 and control 2. Control 1 and control 2 hiPSC-VSMC
ulting cell numbers from replicate derivations of VSMCs from Y6,
independent experiments). (C) Graph showing percentage of VSMCs
) Representative immunofluorescence images of cells stained with
e stains for nuclei. Scale bar represents 50 mm.
es of FBS. (E) Quantification of cell numbers generated from hiPSC-
dent experiments). (F) Graph showing percentage of positive VSMCs
unofluorescence images of cells stained with calponin and SM-22a.
e bar represents 50 mm. The data are represented as means ± SD. Also
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Figure 3. Tissue Ring Fabrication and Characterization Using Y6 hiPSC-VSMCs
(A) Schematic showing tissue ring fabrication by cellular self-assembly, and photographs of tissue rings in the agarose mold (black arrow)
and a harvested tissue ring.
(B) Histochemical analysis of the tissue rings with H&E (left) and Masson’s trichrome (TRI: right) staining. The pink in H&E staining
represents cytoplasm and the blue in Masson’s trichrome represents collagen. The dark purple in both H&E and Masson’s trichrome staining
represents nuclei. Scale bars represent 500 and 100 mm, respectively, for lower and higher magnification images.
(C) Immunofluorescence analysis of calponin (green), SMA (red), SM-22a (green), and SM-MHC (red) present in the tissue rings after
14 days in culture. Blue stains for nuclei. Scale bar represents 50 mm. Also see Figure S4.that hiPSC-VSMCs within tissue rings cultured for 14 days
were positive for calponin, SMA, SM-22a, and SM-MHC
(Figure 3C), suggesting that the cells retained a VSMC
phenotype during culture as self-assembled, high-density
VSMC tissue rings.
Tissue rings from two independent batches were me-
chanically strongwhen harvested after 14 or 17 days in cul-
ture (Figure 4). Stress-strain plots were generated from each
of the tissue ring samples tested (representative plot shown24 Stem Cell Reports j Vol. 7 j 19–28 j July 12, 2016in Figure 4A) and used to calculate ultimate tensile strength
(UTS) andmaximum tangentmodulus. Mechanical testing
data for both batches of Y6 hiPSC-VSMC rings are summa-
rized in Figure 4B. The average thickness of the 2mm inner
diameter tissue rings was 0.84–0.87mm after 14–17 days in
culture. Overall, hiPSC-VSMCs exhibited greater UTS than
14-day-old rat aortic or human coronary artery SMC rings
(2 mm, inner diameter) reported previously (Gwyther
et al., 2011a, 2011b). In addition, the contractile response
Figure 4. Mechanical and Functional Characterization of hiPSC-VSMC Rings
(A) Representative stress-strain curve of a 14-day-old tissue ring (inset, digital image of ring used to measure thickness and calculate
cross-sectional area; scale = 1 mm).
(B) Results of mechanical tests from two independent batches of hiPSC-VSMC tissue rings (mean ± SD; n = 7 and 3 independent mea-
surements for day 14 and 17, respectively).
(legend continued on next page)
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of the hiPSC-VSMC tissue rings in response to agonists,
carbachol (1 mM) and KCl (50mM), was measured (Figures
4C and 4D). The contractility was measured using an in-
strument with a force transducer, in which a contraction
by the rings in response to agonists induces an increase
in force (Figure 4C). The contraction was shown as tension
(Pascal) by a normalizing force with their respective cross-
section areas. The rings showed a contraction of 67.35 ±
22.7 Pa in response to carbachol, whereas the response
was 44.44 ± 27.13 Pa for KCl (Figure 4D).
Furthermore, we tested whether the tissue ring system
could be used to model vascular proliferative diseases
such as supravalvular aortic stenosis (SVAS) syndrome. In
SVAS, hyperproliferation of VSMCs leads to blockage of
the aorta and arteries. Highly enrichedVSMCswere derived
from control and SVAS (Ge et al., 2012) hiPSCs (Figure S4E).
Tissue rings were successfully fabricated from these hiPSC-
VSMCs. The tissue rings were characterized for their differ-
ence in contractility and percent of proliferating cells using
Ki67 immunostaining. The ring contractility study showed
control rings with a contraction of 42.01 ± 11.77 Pa in
response to carbachol, whereas the response was 5.51 ±
4.51 Pa for SVAS rings (Figure 4E). The percentage of
Ki67-positive cells was 6.31% ± 3.16% for control rings
and 21.73% ± 11.96% for SVAS rings (Figures 4F and 4G).
Immunofluorescence analyses of cultured cells revealed
more actin filament bundle formation in the control
iPSC-VSMCs than in the SVAS iPSC-VSMCs (Figure S4E),
consistent with the results described in our earlier report
(Ge et al., 2012). In addition, there was an increased per-
centage of cells expressing SM-MHC in the control iPSC-
VSMCs compared with the SVAS iPSC-VSMCs (Figure S4E).DISCUSSION
In this study, we generated an abundant and renewable
source of functional VSMCs from multiple hiPSC lines.
The success of VSMC production appears to be indepen-
dent of the somatic cell sources (Y6: fibroblasts; control 1,
VSMCs; control 2, peripheral blood mononuclear cells)(C) Photograph showing VSMC tissue ring hooked on two micromani
containing Tyrode’s solution for the contractility assay.
(D) Graph showing change in contractility (Pascal) in response to th
(E) Graph showing change in contractility (Pascal) of control and S
performed to determine statistical difference between different group
used as negative control.
(F) Graph showing percent number of Ki67-positive cells in control
Student’s t test was performed to determine statistical differenc
***p < 0.001).
(G) Representative immunofluorescence images of control and SVAS
represents 50 mm. Also see Figure S4.
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grating SeV; control 1, lentiviral) used to generate the
hiPSC lines. The feeder-free culture approach resulted in
healthier and robust EBs, enabling us to derive40million
VSMCs within 21 days of differentiation time from a 6-well
plate of hiPSCs. The VSMCs were highly enriched for SM-
22a, SMA, and calponin and can further be induced into
mature VSMCs expressing SM-MHC and elastin. The
VSMC derivation method was found to be efficient with
different hiPSC lines and also with different batches of
FBS. The hiPSC-VSMCs were functional and responded to
chemical stimuli such as carbachol and KCl. We have also
investigated different VSMC subtypes using an assay
described previously (Cheung et al., 2012). hiPSC-VSMCs
showed significant proliferation in response to serum, but
only exhibited a modest trend of response upon treatment
with TGF-b1 or angiotensin II without reaching statistical
significance. These results suggest that hiPSC-VSMCs
derived in this study may contain a significant population
of VSMCs derived from the lateral plate mesoderm.
We then used a cellular self-assembly approach to create
hiPSC-VSMC tissue rings. Histological analysis of 14-day-
old rings showed high cellularity andVSMCmarker expres-
sion, including SMA, SM-22a, calponin, and SM-MHC.
Type I collagen was also abundantly found in these tissue
rings. hiPSC-VSMC tissue rings are mechanically strong
enough to endure physical handling and mechanical
testing within 7–14 days of cell seeding. In addition, we
measured normal and SVAS hiPSC-VSMC contractility in
3D tissue constructs, suggesting that the ring self-assembly
system, coupled with patient-specific VSMCs, can be used
to create functional model human vascular tissues. SVAS,
an autosomal disease, is caused by loss-of-function muta-
tions in the elastin gene and is characterized byhyperprolif-
erationofVSMCs leading toblockage of the ascending aorta
andother arterial vessels (Ge et al., 2012). PatientswithWil-
liams-Beuren syndrome (WBS) also display SVAS (Ge et al.,
2012). Earlier 2D studies in cell culture (Ge et al., 2012; Kin-
near et al., 2013) reveal that SVAS andWBS iPSC-VSMCs are
less contractile and more proliferative than control iPSC-
VSMCs. We were able to model these two importantpulators and immersed in a temperature-controlled perfusion bath
e agonists KCl and carbachol. PBS was used as negative control.
VAS rings in response to carbachol. Unpaired Student’s t test was
s (mean ± SD; n = 3 independent experiments, **p < 0.01). PBS was
and SVAS rings. The data are represented as mean ± SD. Unpaired
e between different groups (n = 3 independent experiments,
rings stained with Ki67. Red (Ki67) and blue (nuclei). Scale bar
characteristics of SVAS in the physiologicallymore relevant
3D tissue rings. The SVAS tissue rings showed significantly
less contractility and more proliferative cells than control
rings. The lower contractile forces generated by SVAS rings
might be due to decreased formation of actin filament bun-
dles and fewer cells expressing SM-MHC in SVAS VSMCs
compared with those in control VSMCs.
Primary tissue- or hiPSC-derived VSMCs have been previ-
ously used to establish vascular tissue constructs with
different scaffold materials, such as polyglycolic acid,
fibrin, and poly-L-lactic acid (Bajpai et al., 2012; Niklason
et al., 1999; Sundaram et al., 2014;Wang et al., 2010). How-
ever, these artificial materials are significantly different
from the natural extracellular matrix produced by VSMCs.
In contrast, our unique scaffold-free technique has enabled
fabrication of patient-specific tissue constructs engineered
entirely from human VSMCs and the extracellular matrix
they produce. The facile, one-step cell-seeding process re-
sults in robust, scaffold-free tissue constructs within a short
duration of culture time (less than 2 weeks) without
specialized equipment. Finally, these tissue rings may be
useful asmodular building blocks to generate tubular tissue
constructs to be used for vascular grafts (Gwyther et al.,
2011a, 2011b), or as model in vitro vascular tissues for
drug discovery and to study human disease mechanisms.
In the future, we will fabricate tissue rings from various
lineage-specific hiPSC-VSMCs and disease-specific VSMCs
for disease modeling and drug screening. Further optimiza-
tion of the culture conditions such as use of Ficoll, amacro-
molecular crowder, in the culture medium will be tested in
order to enhance the strength of the tissue rings (Zeiger
et al., 2012). Finally, our methodology can potentially be
extended to fabricate tissue rings from other types of cells
derived from patient-specific hiPSCs for the construction
of mechanically robust engineered tissues for disease
research and treatment.EXPERIMENTAL PROCEDURES
Animal Studies
Immunodeficient Rag2-/-GammaC-/- mice were used for teratoma
assay. All animal studies were approved by the Yale IACUC proto-
col (2013-11347) and performed in accordance with the NIH
guidelines for care and use of laboratory animals.hiPSC-VSMC Derivation
hiPSC-VSMCswere derived using amodified EB protocol which re-
sults in a larger-scale generation of VSMCs at the end of 21 days. A
detailed protocol is described in the Supplemental Information.Tissue Ring Fabrication
Custom agarose molds for tissue ring formation were made as pre-
viously described (Gwyther et al., 2011a, 2011b), withminormod-ifications (Dikina et al., 2015). A detailed protocol is described in
the Supplemental Information.
2D and 3D Contractility Study
The 2D SMCcontraction studywas carried out usinghiPSC-VSMCs
cultured on tissue culture plastic. KCl (50 mM) and carbachol
(1 mM) were used as agonists. Similarly, tissue rings were tested
for their contractility in response to carbachol. A detailed protocol
can be found in the Supplemental Information.
Tissue Ring Mechanical Testing
Mechanical testingwas performed using an uniaxial tensile testing
machine (Electropuls E1000, Instron) as previously described
(Gwyther et al., 2011b). A detailed protocol can be found in the
Supplemental Information.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6. One-
way ANOVA was used to compare the cell proliferation between
different time points, and two-tailed Student’s t test was used for
pair comparisons.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and two tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2016.05.004.
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